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Summary
Background Initial studies suggested that polymorphisms in Tim1 and Tim3 contribute to the
development of airway hyperreactivity (AHR) in an acute mouse model of asthma. This was
also mirrored in human genetic studies where polymorphisms in Tim1 and Tim3 have been
associated with atopic populations.
Objective Further studies using anti-Tim1 or -Tim3 antibodies, or Tim fusion proteins, have
also suggested that these molecules may function as regulators of type-1 and type-2
immunity. However, their role in the development of AHR and airway inﬂammation remains
unclear. Given the proposed roles for Tim1 and Tim3 in type-1 and type-2 responses, we
sought to determine whether these molecules were important in regulating antigen-driven
lung allergy and inﬂammation.
Method We used Tim1- and Tim3-deﬁcient mice and determined how the development of
allergic lung inﬂammation was affected.
Results AHR was induced normally in the absence of both Tim1 and Tim3, although
Tim1-deﬁcient mice did show a small but signiﬁcant decrease in cell inﬁltration in the lung
and blood eosinophilia. Although Tim3 was expressed on CD4
1 T cells in the allergic lung,
Tim1 expression was restricted to CD86
1 B cells.
Conclusions and clinical relevance Thus, Tim1 and Tim3 are not essential for the induction of
the type-2 response in lung allergy. This is contrary to what was proposed in a number of
other studies using neutralizing and activating antibodies and questions the clinical relevance
of Tim1 and Tim3 for novel allergy therapies.
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Introduction
Asthma is a complex chronic, inﬂammatory lung disease
and is the most common chronic childhood disease
affecting developed nations. The Th2 cytokine gene clus-
ter, located on human chromosome 5q31-35, is clearly an
important genetic determinant in asthma susceptibility.
Interleukin 4 (IL-4), IL-5, IL-9, and IL-13 have all been
shown to be essential components of the asthmatic
response, including airway hyperreactivity (AHR), mucus
hypersecretion, and B cell isotype-switching to IgE [1–6].
However, mapping studies have also identiﬁed the Tapr
(T cell and airway phenotype regulator) locus on mouse
chromosome 11, linked to the Th2 cytokine gene cluster,
which conferred susceptibility to ovalbumin (OVA)-in-
duced AHR in an experimental mouse model of asthma
[7]. Polymorphisms in Tim (Tcell immunoglobulin mucin)
1(Havcr1) and Tim3 (Havcr2), two membersof a new gene
family discovered within the Tapr locus, were found to
correlate with AHR and Th2 cytokine production,
although the relative importance of Tim1 and Tim3
to this phenotype was unclear. McIntire et al. [8] have
since reported that atopic resistance can be correlated
with hepatitis A virus seropositivity and an insertion
mutation in human TIM1, previously identiﬁed as the
hepatitis Avirus receptor (HAVCR1), suggesting that TIM1
may provide a biological basis for the link between
decreasing exposure to HAV and the increasing incidence
of atopy in westernized society. Associations between a
number of mutations in both TIM1 and TIM3 and atopic
disease have been found in other human asthma studies
[9, 10].
Experimental Models of Allergic Disease
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(Tim1HuIg) fusion protein, or ligation of Tim1, either by
a proposed counter-ligand in the form of a Tim4HuIg
fusion protein [11], or an agonistic anti-Tim1 (clone 3B3)
monoclonal antibody [12], resulted in the costimulation of
T cell activation and the enhancement of IL-4 and IFN-g
production by CD3
1 T cells. In vivo administration of the
anti-Tim1 antibody (clone 3B3) prevented the develop-
ment of respiratory tolerance and increased pulmonary
inﬂammation [13], suggesting that blocking Tim1 func-
tion may suppress type-2 responses such as those ob-
served in allergic inﬂammation. Indeed, Encinas and
colleagues showed a down-regulation of OVA-induced
allergic inﬂammation following anti-Tim1 antibody
(clone 222414) treatment. However, recent reports have
demonstrated that the interactions of antibodies recogniz-
ing different epitopes on Tim1 can mediate diametrically
opposite effects. Anti-Tim1 antibodies, distinguishing
speciﬁc epitopes in both the immunoglobulin (Ig) region
and the mucin domain, were shown to reduce lung
eosinophilia and lung inﬂammation, whereas an antibody
directed at a different epitope in the mucin domain
actually exacerbated the allergic response [14]. Further-
more, even anti-Tim1 antibodies recognizing the same
epitope (clones 3B3 and RMT1-10), but with different
avidities for Tim1, have been reported to elicit opposite
functional effects [15]. Administration of a neutralizing
anti-Tim3 antibody (clone 8H7), although ineffective
when administered during an OVA sensitization and
challenge model of asthma, was able to induce a partial
decrease in AHR and Th2 cytokine production following
the transfer of OVA-speciﬁc in vitro differentiated Th2
cells [16].
Thus, studies to date leave an unclear picture as to the
importance of Tim1 and Tim3 in allergic asthma re-
sponses. To clarify the functional requirement for Tim1
and Tim3, we have analysed Tim1- and Tim3-deﬁcient
mouse lines and assessed the potential roles of these
molecules in an in vivo model of antigen-driven acute
lung allergy.
Materials and methods
Targeted disruption of the mouse Tim1 and Tim3 genes in
embryonic stem cells
The Havcr1 (Tim1
 / ) mice were generated as described
previously [17]. The Havcr2 (Tim3
 / ) replacement vector
was constructed to insert the neomycin resistance gene
into exon 2 of the Havcr2 gene. This deleted the nucleo-
tides encoding 71 amino acids (Phe57 – Lys127) of the 281
amino acid coding sequence of the Tim3 gene. The 4.1kb
50 arm of homology was generated using E14.1 129J
embryonic stem (ES) cell DNA as a template with PCR
primers 50-CAGCAATGCGGCCGCGTAAGCCAAATAAA
CCCTTTCCTACCTAGC-30 and 50-GGACAGGATCCCTTGCC
CCAGCACATAGGCACAAGT G-30. The 2.0kb 30 homology
arm was generated using RPCI21 PAC488-E20 as a tem-
plate with PCR primers 50-ATTAGAACTAGTATT AGA-
CATCAAAGCAGGTGAGTAG-30 and 50-AATCCTACTAGT
GGCCTATATGGTAGATAACTATATG-30. The Havcr2 tar-
geting vector was linearized and electroporated into E14.1
129J ES cells and used to generate mice homozygous for
the gene by standard methods. Tim3
 /  mice, and corre-
sponding wild-type animals, were derived from the origi-
nal chimeras. Sequencing of Tim1 and Tim3 transcripts
from BALB/c and 129 sources identiﬁed no polymorph-
isms between these strains; thus, mice were backcrossed
for six generations to the BALB/c strain before intercross-
ing to generate homozygous mice. Genotypes were
screened by southern analysis or PCR using primers,
50-TGGTAAGAATGCCTATCTGCC-30 and 50-TCTGTAGAC-
CATATCCTGGAGTTC-30. The oligonucleotide speciﬁc to
the inserted neomycin cassette was 50-CTATCAGGACA-
TAGCGTTGGCTACC-30. All mice were maintained in a
speciﬁc pathogen-free environment in SABU/CBS facil-
ities according to UK Home Ofﬁce regulations.
RNA preparation
RNA was prepared from naı ¨ve tissues and from in vitro
differentiated T helper cells [17] using RNAzolB, accord-
ing to the manufacturer’s instructions (AMS Biotechnol-
ogy, Oxford, UK). Tim3 RT-PCR primers were as follows:
50-AGGTCATTGGAAAATGCTTATGTGTTTGAG-30 and
50-CAGTAGGTCCCATGGTCATCC-30,5 0-CTGCTGCAGGA
TACAGTTCCC-30 and 50-GAAATTAAGGACTCTGGAGA
AACGATCAGAAC-30,5 0-GAAATTAAGGACTCTGGAGAA
ACGATC-30 and 50-GCTACGTCAACAGAAAGCAGCCAT
CC-30. HPRT primers and conditions were as described
previously [18].
Flow cytometry
Lung cell suspensions, treated with 720mg/mL collage-
nase D (Amersham, Bucks, UK), were analysed for the
expression of Tim1 and Tim3 by ﬂow cytometry using the
FACScalibur (BD, Biosciences, Oxford, UK) and FlowJo
analysis software. Biotin-conjugated anti-Tim1 (clone
RMT1-4, eBioscience SanDiego, CA, USA), biotin-conju-
gated anti-Tim3 (clone 8B.2C12, eBioscience), and PE-
conjugated streptavidin were used.
Sensitization and allergen exposure
BALB/c mice (6–12 weeks) were sensitized by an intraper-
itoneal administration of OVA (20mg/injection, endotoxin
low – removed using Afﬁniti Pak Endotoxin Removing
Gel Columns (Pierce, Rockford, IL, USA) according to
the manufacturer’s instructions) in PBS (endotoxin free
  c 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 41 :1012–1021
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complexed in a 1:1 ratio with alum (Imject
s, Thermo
Scientiﬁc, Loughborough, UK), at days 0 and 12. Control
mice received PBS only with alum. Aerosol administration
of 1% OVA was undertaken on days 19, 20, and 21 for
20min/day. Control animals received PBS.
Measurement of airway resistance
On day 22, animals were analysed using invasive lung
function measurements (EMMS, Bordon, UK) to assess
AHR. Animals were anaesthetized, tracheostomized, and
placed on a ventilator (MiniVent 845 ventilator, EMMS) at
a rate of 150breaths/min, with a tidal volume of 0.15mL.
After recording stable baseline pulmonary resistance for
3min, increasing concentrations of acetyl-b-methylcho-
line chloride (methacholine) (Sigma-Aldrich) were admi-
nistered by aerosol for 10s at each concentration using an
ultrasonic nebulizer, and pulmonary resistance was re-
corded for a 3-min period. eDaq software was used to
analyse airway resistance.
Tissue collection
Lungs were ﬁxed in formalin (10% formaldehyde in a 0.9%
saline solution) and stained with Giemsa, for inﬂammatory
inﬁltrate, and periodic acid-Schiff (PAS) for mucus-produ-
cing goblet cells. Airway mucus production and numbers of
inﬁltrating cells around blood vessels were measured blind
using numerical scoring systems. Mediastinal lymph node
cells were re-stimulated with 100mg/mL OVA or 1mg/mL
puriﬁed anti-CD3 and cell supernatants were taken at a 72h
time-point. BALﬂuid was collected, according topreviously
described protocols [19].
Differential white blood cell counts and
3[H]-thymidine
cell proliferation assay
Blood smears were stained with Giemsa (Sigma-Aldrich),
following the manufacturer’s instructions. Differential
cell counts were made blind on 100 white blood cells per
slide under oil and at a  63 magniﬁcation. Blood was
incubated at 41C overnight and serum was collected by
centrifugation. Measurement of cell proliferation was
undertaken as described previously [17] with or without
30mg/mL IgM (AfﬁniPure F(ab0)2, m chain speciﬁc, Jack-
son Laboratories, Bar Harbor, ME, USA).
Cytokine and serum immunoglobulin enzyme linked
immunosorbent assays
Cytokine ELISA utilized the sandwich format with capture
and detection antibodies purchased from Becton Dickin-
son. ELISAs were performed according to the Becton
Dickinson ELISA protocol. IL-13 was measured using the
Quantikine ELISA kit (R&D Systems, Abingdon, UK). OVA-
speciﬁc serum Ig ELISAs were undertaken using immuno-
sorbent plates coated with 5mg/mL OVA, overnight, and
then as described previously [17].
Statistical analysis
The signiﬁcance of the differences between experimental
groups was analysed using a two-way ANOVA with Bonfer-
roni post-test (for dose response to methacholine) or the
Student unpaired t-test.
Results
Allergic lung inﬂammation can be induced in the absence
of Tim1
Airway obstruction is the most debilitating symptom of
asthma and is a result of excessive contraction of smooth
muscle. Bronchoconstriction can be determined during
allergic lung inﬂammation using invasive plethysmogra-
phy to directly measure airway resistance in response to
lung agonists, e.g. methacholine. To investigate a role for
Tim1 in allergic disease, wild type and Tim1
 /  mice were
ﬁrst sensitized intraperitoneally and then challenged in
the lung with aerosolized OVA to induce a type-2
mediated inﬂammatory response. As expected, the airway
resistance in OVA-treated wild-type mice increased com-
pared with PBS-treated control mice (Fig. 1a). Tim1
 / 
mice displayed a minor, although statistically signiﬁcant,
reduction in airway resistance at the 20mg/mL methacho-
line dose, but overcame this deﬁcit at higher doses
(40–80mg/mL).
We also investigated the requirement for Tim1 during
the allergic lung inﬂammatory response. The total cell
counts from the bronchoalveolar lavage (BAL) showed
that the numbers of lymphocytes, macrophages, eosino-
phils, and polymorphonuclear leucocytes (PMNLs) were
equivalent in the PBS-treated Tim1
 /  and wild-type
mice (Fig. 1b). OVA treatment led to a minor, but statisti-
cally signiﬁcant, decline in lymphocyte and eosinophil
cell numbers in the BAL of Tim1
 /  mice, as compared
with wild-type mice (Fig. 1b). However, eosinophils, the
main inﬁltrating cell, still increased signiﬁcantly in OVA-
treated Tim1
 /  mice compared with PBS-treated control
mice (Fig. 1b).
To explore whether the reduction in inﬁltrating cells
resulted from an inability to migrate or home efﬁciently,
or from a deﬁcit in circulating eosinophils, we examined
blood cell composition. Differential blood cell counts of
lymphocytes, monocytes, eosinophils, and PMNLs were
performed on samples from the PBS- and OVA-challenged
mice. Blood eosinophils constituted  2% of leucocytes in
wild-type and Tim1
 /  PBS control mice. In wild-type
OVA-treated mice, this was increased to around 12%.
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 /  mice failed to develop
equivalently severe eosinophilia (Fig. 1c). No other blood
cell types were altered by the Tim1 deﬁciency (data not
shown). The coincident decrease in the levels of circulat-
ing eosinophils and lung inﬁltrating eosinophils implies
that the deﬁcit in cellular inﬁltrate arises from the reduc-
tion in circulating cells rather than an inability to migrate
to the lungs.
The deﬁcit in cellular inﬁltrate observed in the BAL
of Tim1
 /  mice was also mirrored in the lung tissue.
Here, the perivascular cell inﬁltrate score was again
signiﬁcantly lower, but not completely abrogated, in
the Tim1
 /  lungs (Fig. 1d). It is not clear whether this
relates to a decrease speciﬁcally in lung eosinophils.
Mucus production, identiﬁed by PAS staining of airway
epithelium, was similar in the OVA-treated wild type and
Tim1
 /  groups (Fig. 1e).
As Tim1 is reportedly expressed on CD4
1 Th2 cells, we
investigated the proliferation and cytokine responses in
OVA-restimulated cells cultured from the draining med-
iastinal lymph nodes. Cells from OVA-challenged mice
produced very little antigen-speciﬁc IL-2 and no IFN-g
(data not shown), but elevated levels of the Th2-cytokines
IL-4 and IL-5 (Fig. 2a). The levels of IL-5 were slightly
reduced in the Tim1
 /  samples, but this did not attain
statistical signiﬁcance. Although IL-4 could not be de-
tected in the BAL ﬂuid, OVA-induced IL-5 and IL-13 levels
were found to be normal in Tim1
 /  mice (Fig. 2b). The
proliferation of mediastinal lymph node cells from wild-
type and Tim1
 /  mice, in response to OVA, also demon-
strated no appreciable differences between the OVA-chal-
lenged groups (data not shown). Collectively, these data
show that OVA-induced T cell proliferation and cytokine
responses do not appear to be signiﬁcantly affected by
Fig. 1. (a) Airway resistance in wild type and Tim1
 /  mice measured using invasive plethysmography. Results are shown for lung resistance above the
baseline reading. P=o0.001 between wild-type PBS and ovalbumin (OVA)-treated mice. ‰P=o0.05 between wild-type and Tim1
 /  OVA-treated
mice. (b) Differential cell counts were performed on the BAL ﬂuid in 250mL from wild-type and Tim1
 /  mice. (c) The percentages of eosinophils in
peripheral blood were assessed by differential cell counts. (d) Cellular inﬁltration and (e) mucus production determined by analysis of lung sections
stained with Giemsa or periodic acid-Schiff, respectively.  20 magniﬁcation. Data are representative of two to three repeat experiments (n=8–10).
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response.
Tim1 is predominantly expressed on activated B cells, not
T cells during allergic lung inﬂammation
The lack of a demonstrable effect on type-2 cytokine
production is at odds with the existing dogma regarding
Tim1 bioactivity and its reported expression on Th2 cells.
Thus, we undertook extensive studies to demonstrate
convincing staining for Tim1 on the surface of naı ¨ve T
cellsor differentiated Th1 or Th2 cells.During our analysis
of the cell surface expression of Tim1, we used the anti-
Tim1 antibody RMT1-4 (16) due to it consistently recog-
nizing Tim1 as assessed by its binding to native Tim1,
transgenically expressed Tim1 of either the BALB/c or the
C57BL/6 allotype (data not shown), and its failure to stain
cellular products in the Tim1-deﬁcient mice (Fig. 3a).
Signiﬁcantly, we were unable to ﬁnd any detectable
Tim1 expression by ﬂow cytometric analysis on
CD3
1CD4
1 or CD3
1CD8
1 T cell populations in either
naı ¨ve or allergic lung tissue (data not shown). However,
further investigation of the expression pattern of Tim1
showed that it was detectable on CD4
 CD8
  cells, and
restricted within that population to CD19
1 B cells from
naı ¨ve lung tissue (Fig. 3a and b). We found no evidence for
Tim1 expression on any other cell population at this time-
point. Furthermore, Tim1 was up-regulated on B cells
after induction of allergic lung inﬂammation (Fig. 3b).
Additionally, further phenotypic analysis indicated that
the Tim1 expression during lung allergy coincides with
CD86 expression on the B cells, suggesting that it is
expressed on activated B cells capable of co-stimulation
of T cell activation (Fig. 3c). Although B cells have not
been shown to be essential for allergic lung inﬂammation,
the expression of Tim1 on CD19
1CD86
1 cells led us to
investigate whether Tim1
 /  mice had defects in B cell
function following the induction of lung allergy. To test
this, the production of OVA-speciﬁc serum Igs was ana-
lysed. In wild-type mice, OVA treatment induced a large
increase in OVA-speciﬁc IgG1 and IgE antibodies, and
some IgA and IgG2b antibodies, as well as an increase in
total IgE production (Fig. 3d and e). No defects were found
in serum antibody production during allergic lung in-
ﬂammation in Tim1
 /  mice. Similarly, the proliferative
response of B cells from Tim1
 /  mice following IgM
stimulation in vitro was also found to be normal (Fig. 3f).
Therefore, B cell function was not found to be affected by
deﬁciency in Tim1.
Tim3 is expressed on CD11c
1 myeloid cells and
CD4
1CD25
1 T cells during allergic lung inﬂammation
Tim3, likeTim1, has also been associated with a number of
human diseases including multiple sclerosis and rheuma-
toid arthritis, and has been shown to be expressed on
CD4
1 Th1 cells in mice. Components of the type-1
immune response have previously been shown to affect
the allergic lung response. To address the potential role of
Tim3 in experimental asthma, we developed a mouse line
deﬁcient for Tim3 (Havcr2) by gene targeting in ES cells
Fig. 2. Ovalbumin (OVA)-speciﬁc and polyclonal cytokine production was determined from (a) restimulated mesenteric lymph node cell cultures and (b)
BAL ﬂuid samples by sandwich ELISA. Data are representative of two repeat experiments (n=8–10).
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 /  mice were
healthy and displayed no overt phenotypic abnormalities.
We ﬁrst wanted to ascertain Tim3 expression during the
allergic response. Lung tissue was taken from wild-type
and Tim3
 /  mice, in which lung allergy had been
induced. Tim3 expression in these mice was compared
with that in PBS control mice. No differences in the
percentage of CD4
1 or CD8
1 T cells, CD19
1 B cells, or
CD11c
1 alveolar macrophages were observed between
wild-type and Tim3
 /  mice (data not shown). Tim3 was
expressed in naı ¨ve wild-type mice only on CD11c
1 lung
cells (Fig. 4a). The expression of Tim3 was increased on
CD11c
1 cells in OVA-treated mice. Although CD11c is
normally considered to be a surface marker for dendritic
cells, in the lung, it is expressed mostly on alveolar
macrophages. Tim3 expression was also found on
CD4
1CD25
1 cells. Notably, these cells were only observed
in OVA-treated mice (Fig. 4b). Thus, although Tim3 has
been associated in previous reports with type-1 immunity,
our data show that Tim3 is up-regulated during the type-2
response in allergic lung inﬂammation.
Tim3 is not required for the induction of allergic lung
inﬂammation
As Tim3 was expressed in the lung during allergic
responses, we next wanted to test its functional signiﬁ-
cance in those responses. We were unable to measure any
detectable differences in airway resistance, compared with
the OVA-treated wild-type mice, caused by the absence of
Tim3 (Fig. 5a).
In agreement with the airway resistance data, the
absence of Tim3 also exerted no detectable effect on the
Fig. 3. (a) Mean ﬂuorescence intensity of Tim1 expression on CD4
 CD8
  in the lung as assessed by ﬂow cytometry. (b) Left panel, histogram of CD19
 
and CD19
1 gated populations in the lung. Middle and right panel, Tim1 expression within the CD19
  gate and CD19
1 gate, respectively, in the lung.
Grey line, PBS -treated mice; black line, ovalbumin (OVA) mice; ﬁlled grey, isotype control. (c) OVA-speciﬁc IgA, IgE, IgG1, and IgG2b, and (d) total IgE
production in serum. (e) Mediastinal lymph node cell proliferation in response to media only or IgM, measured by the incorporation of
3[H]-thymidine.
Data are representative of two repeat experiments (n=8–10).
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lung, as assessed by BAL cell counts and lung histology,
was comparable to wild-type controls (Fig. 5b and c).
Furthermore, blood eosinophilia and airway mucus pro-
duction were also found to be normal in the Tim3-
deﬁcient mice, as were type-2 cytokine responses in the
BAL ﬂuid, as measured by IL-5 production (Fig. 5d–f).
Cytokine production from draining lymph node cells, and
Fig. 4. (a) Histograms showing Tim3 expression on CD11c
1 gated cells and (b) T cells in the lungs of mice treated with PBS or ovalbumin (OVA). T cells
were gated as being CD4
1CD25
1/  by ﬂow cytometry. Average percentages for three mice per group are shown. Regular text, wild type; italic text,
Tim3
 / . Data are representative of two repeat experiments.
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tion, were also unchanged by the absence of Tim3 (data
not shown).
Discussion
Using Tim1
 /  and Tim3
 /  mice, we have investigated
the role of these molecules in the regulation of type-2
responses during lung allergy. Although previous reports
have implicated both Tim1 and Tim3 as being important
components of the T cell cytokine response, we now
demonstrate that Tim1 and Tim3 are dispensable in
regulating AHR in a mouse model of allergic asthma.
Th2 cell responses seem to remain largely intact in the
absence of Tim1 and Tim3, although in Tim1
 /  mice,
there are minor, but statistically signiﬁcant, reductions in
lung function measurements at low methacholine con-
centrations, blood eosinophilia, and lung cell inﬁltration.
It is unclear what underlies these small defects, but does
suggest that Tim1 is largely not required for the response
to proceed. We were unable to detect a statistically
signiﬁcant deﬁcit in OVA-speciﬁc IL-5 production from
the draining lymph node cells, or BAL ﬂuid, from Tim1
 / 
mice. However, it remains possible that levels of IL-5 and
eotaxin, or other granulocyte growth factors such as GM-
CSF, may be suppressed at other time-points in the
response, thereby underlying this deﬁcit in circulating
eosinophils.
Encinas et al. [13] previously demonstrated, using an
anti-Tim1 mAb (clone 222414), that pulmonary inﬂam-
mation, and IL-10 and IL-13 levels were reduced follow-
ing anti-Tim1 administration, suggesting that Tim1 was
required to induce normal allergic lung inﬂammation.
Although we observed minor reductions in eosinophil
inﬁltration, we did not detect a signiﬁcant reduction in
type-2 cytokine production from cells isolated from the
draining lymph nodes and Tim1 was not essential for AHR
or substantial lung inﬂammation.
One striking observation made from our analysis of
naı ¨ve mice, using Tim1-deﬁcient mice as negative con-
trols for the cell surface staining of Tim1, was the
predominant expression of Tim1 on the surface of a B cell
population, and not T cells during lung allergy. Although
the Tim1 transcript has been reported previously in B cell
cDNA from both the spleen and the lymph nodes in
BALB/c and C57BL/6 mice, and Tim1 expression has been
noted on activated B cells, further characterization in vivo
was not undertakenin the lung [17]. We found that Tim1
1
B cells were characterized as CD19
1CD86
1 B cells, prob-
ably representing a more activated B cell population.
Moreover, following in vitro B cell activation with the
Fig. 5. (a) Airway resistance in wild-type and Tim3
 /  measured using invasive plethysmography. Results are shown for lung resistance above the
baseline reading. (b) Differentialcell counts were performedon the BALﬂuid in 250mL from wild-typeand Tim3
 /  mice. (c) Cellularinﬁltrationand (d)
mucus production determined by analysis of lung sections stained with Giemsa or PAS, respectively.  20 magniﬁcation. (e) The percentages of
eosinophils in peripheral blood were assessed by differential cell counts. (f) IL-5 production in the BAL ﬂuid as measured by ELISA. Data are
representative of two to three repeat experiments (n=8–10).
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expressed on almost all proliferating B cells, highlighting
the regulation of Tim1 expression on activated B cells
[17]. By contrast, we failed to observe the regulation of
Tim1 on T cells, although it is possible that Tim1 is
expressed on T cells during other types of immune
response.
The role of up-regulated Tim1 in B cells remains
uncertain, but the fact that it is induced by activation
through the B cell receptor, but not via LPS stimulation
[17], indicates that Tim1 is differentially regulated de-
pending on the antigenencountered and that it may play a
role in forming these divergent responses. Following lung
challenge, while ﬂow cytometric analysis failed to identi-
fy Tim1
1 T cells in the lungs, CD19
1Tim1
1 B cells were
identiﬁed and these were also CD86
1. Thus, Tim1 appears
to be a marker of a subset of activated B cells during in
vivo immune responses to antigen. Despite the expression
of Tim1 on B cells, we found no alteration in Ig expression
or B cell proliferation. Wong and colleagues also failed to
ﬁnd a role for Tim1 on B cells in antigen presentation in
the spleen.
We also found no measurable role for Tim3 in this OVA-
induced model of allergic asthma, although unlike Tim1,
it was expressed on a population of CD4
1CD25
1 cells,
which would classically be considered to be either T
regulatory cells or activated T cells. Our results contrast
with the report by Kearley et al. [16], in which OVA-
induced airway inﬂammation was reduced following
treatment with an anti-Tim3 antibody and correlated with
a decrease in IL-5 expression. However, these differences
were only observed in a model involving the transfer of in
vitro generated Th2 cells into naı ¨ve recipients, and not in a
more conventional OVA-sensitization model of airway
inﬂammation [16]. Thus, although the modulation of
Tim3 can have an impact on a type-2 response, it is likely
that the effects of inhibiting Tim3 vary considerably
depending on the model used.
Our results were somewhat unexpected, given previous
reports regarding Tim1, suggesting not only that the genes
encoding Tim1 and Tim3 within the Tapr locus, along
with their associated polymorphisms, may play a role in
regulating pulmonary function [7] but that anti-Tim1 and
anti-Tim3 antibodies administered in vivo exerted wide-
ranging effects on T cell function during diabetes [20],
transplant rejection [20], pulmonary inﬂammation [12],
and EAE [21]. These differences may reﬂect the variation
in the biological effects that have been reported for the
interaction of anti-Tim1 antibodies with agonistic and
antagonistic epitopes on Tim1 [14].
Furthermore, it is possible that there is a functional
redundancy between the Tim family members that also
include Tim2, Tim4, Tim5, and Tim 6. Certainly, Tim2-
deﬁciency has been shown to exacerbate the allergic
inﬂammatory response due to the up-regulation of type-
2 cytokine release by Tcells [22]. However, the roles of the
other family members in such responses are unknown.
Genetic association studies in humans have indicated
that polymorphisms in HAVCR1 correlate with the devel-
opment of atopic disease [8, 23]. Similar studies have also
failed to ﬁnd any such association in a Japanese popula-
tion [24]. We now demonstrate that although Tim1
 / 
mice show a slight decrease in AHR, which probably arises
as a result of a broad-spectrum reduction in lung cell
inﬁltrates, notably eosinophils, the absence of Tim1, or
indeed Tim3, does not prevent the allergic lung response,
suggesting that they may not be clinically relevant targets
for new therapies.
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Fig. S1. Inactivation of Havcr2 (Tim3) by homologous
recombination (A) The structure of the Tim3 locus, the
targeting vector, and predicted homologous recombination
event. (B) Genotyping of genomic DNA from Tim3 gene-
targeted mice by PCR analysis. (C) RT-PCR analysis of Tim3
expression, assessed using exon-speciﬁc primer sets in wild
type and Tim3
 /  Th1 and Th2 cells. Con, vector containing
full length Tim3 transcript; Neg, negative control. (D) Flow
cytometric analysis of Tim3 expression on lung cell suspen-
sions from OVA sensitised wild type and Tim3
 /  mice.
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